New Study: CBG May Help Reverse Fatty Liver Disease
Researchers found CBG improved liver function in lab models
A study published in March 2026 in the British Journal of Pharmacology found that CBG and CBD may help reverse non-alcoholic fatty liver disease (NAFLD). The research came out of The Hebrew University of Jerusalem, and the results got our attention.
NAFLD affects roughly 25% of the global population. It's the most common chronic liver condition in the world, and it's tied directly to diet, obesity, and metabolic dysfunction. There's currently no approved drug treatment for it.
What the study found
The researchers, led by a team at Hebrew University, discovered that CBG and CBD improved how liver cells handle two critical functions: energy metabolism and cellular cleanup.
Specifically, the cannabinoids worked through something called phosphocreatine buffering (how cells manage energy reserves) and lysosomal restoration (how cells break down and recycle damaged material). When these systems malfunction, fat accumulates in liver cells. The cannabinoids appeared to help restore normal function in both pathways.
The study title tells you exactly what they found: "Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration."
Translation: CBG and CBD helped fix the two mechanisms that cause fat to build up in liver cells.
Why CBG specifically matters here
Most cannabinoid liver research has focused on CBD alone. This study looked at both CBD and CBG and found that both contributed to the positive effects. That's significant because CBG remains severely under-studied compared to CBD, and every new piece of research that validates its biological activity moves the needle toward larger human trials.
CBG interacts with the body's endocannabinoid system differently than CBD. It binds to both CB1 and CB2 receptors, and recent research shows it also has affinity for alpha-2 adrenergic receptors and serotonin 5-HT1A receptors. That broader receptor profile may explain why CBG keeps showing up in studies across inflammation, neuroprotection, appetite, antibacterial activity, and now liver health.
What this doesn't mean
This was a preclinical study. It was not conducted on humans. It does not prove that drinking CBG coffee will fix your liver. We're not making that claim and nobody responsibly can at this point.
What it does mean: CBG continues to show biological activity in areas that matter to human health, and the research base is growing. The first human clinical trial specifically studying CBG's effects (Washington State University, NCT06638996) was completed in February 2026. More are in the pipeline.
We chose to build our entire product line around CBG because the early science pointed in this direction. Studies like this one confirm that bet.
The bigger picture
The CBG gummies market alone hit $2.94 billion in 2025 and is projected to grow 45% this year. CBG is no longer a niche cannabinoid that only hemp nerds know about. It's going mainstream, and the research is catching up to the consumer interest.
We've been putting CBG in our coffee since day one. We developed the only water soluble CBG formula on the market. And studies like this one from Hebrew University are exactly why we made those bets early.
Shop CBG coffee and our exclusive water soluble CBG tincture at buddhabeanscoffee.com.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. The research cited is preclinical and does not constitute medical advice.
